Fran Gregory, Pharm.D., MBA is the Vice President of Emerging Therapies at Cardinal Health. She thinks 2024 will be an exciting year for cell and gene therapy.
We asked our readers and some members of our editorial advisory board to make predictions for 2024. Here's what Fran Gregory, Pharm.D., MBA said:
“2024 is going to be an exciting year for cell and gene therapy approvals following a strong end to 2023, including new technology types and indications (sickle cell disease, beta-thalassemia, chronic lymphocytic leukemia and tumor- infiltrating lymphocytes therapy in solid tumors). They all necessitate more precise ways of measuring patient outcomes and improved tracking and visibility for all stakeholders.
We’re anticipating increased payer scrutiny and more of a true focus on innovative payment models given multiple new approvals expected between now and 2025, some of which will be approved in much larger patient populations than we’ve seen so far. Biopharma will continue to focus on earlier and more comprehensive launch planning, including market access and channel strategy to anticipate patient access challenges, build stakeholder education and improve patient services programs to address those needs.”